Piero Galieni

Dr. Piero Galieni

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1996 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ABAlessandro Bucalossi
Alessandro Bucalossi
GMGiuseppe Marotta
Giuseppe Marotta
CBCatia Bigazzi
Catia Bigazzi
PGPiero Galieni
Piero Galieni
EDEgidio Dispensa
Egidio Dispensa
Patients with polycythemia vera (PV) or essential thrombocythemia (ET) show a high frequency of thrombosis. The reduction of hematocrit after phlebotomy and normalization of platelet counts do not completely eliminate thrombotic risk. Some preliminary studies reported a reduction in the concentration of natural anticoagulants (NA) in this group of patients. For this reason we evaluated protein S (PS) total antigen, antithrombin III (AT III), and protein C (PC) activity in 81 patients with chronic myeloproliferative disorders (33 with PV and 48 with ET). Data were compared with those obtained in 70 healthy sex- and age-matched subjects. Fifty-seven percent of patients (46 out of 81) showed one or more thrombotic episodes at diagnosis or during follow-up. Interestingly, we found a NA deficit in 43.5% of patients with thrombosis versus only 5.7% in the group of patients without thrombosis. These results may suggest new interpretations about the pathogenesis of thrombosis in PV or ET patients.

26 May 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
DVDavide Vagnoni
Davide Vagnoni
FTFosco Travaglini
Fosco Travaglini
VPValerio Pezzoni
Valerio Pezzoni
MRMiriana Ruggieri
Miriana Ruggieri
CBCatia Bigazzi
Catia Bigazzi
PGPiero Galieni
Piero Galieni

1 April 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PGPiero Galieni
Piero Galieni
FTFosco Travaglini
Fosco Travaglini
DVDavide Vagnoni
Davide Vagnoni
MRMiriana Ruggieri
Miriana Ruggieri
PCPatrizia Caraffa
Patrizia Caraffa
VPValerio Pezzoni
Valerio Pezzoni


20 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Francesca Romana MauroFrancesca Romana Mauro
Francesca Romana Mauro
PSPotito Rosario Scalzulli
Potito Rosario Scalzulli
LSLydia Scarfò
Lydia Scarfò
carla minoiacarla minoia
carla minoia
RMRoberta Murru
Roberta Murru
Stefano MolicaStefano Molica
Stefano Molica
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use, and clinical outcomes in 309 patients with CLL receiving single-agent ibrutinib in first line (1L, n = 118), 2L (n = 127) and ≥3L (n = 64) in the prospective, real-world, Italian EVIdeNCE study. After a median follow-up of 23.9 months, 29.8% of patients discontinued ibrutinib (1L: 24.6%, 2L: 29.9%, ≥3L: 39.1%), mainly owing to adverse events (AEs)/toxicity (14.2%). The most common AEs leading to discontinuation were infections (1L, ≥3L) and cardiac events (2L). The 2-year retention rate was 70.2% in the whole cohort (1L: 75.4%, 2L: 70.1%, ≥3L: 60.9%). The 2-year PFS and OS were, respectively, 85.4% and 91.7% in 1L, 80.0% and 86.2% in 2L, and 70.1% and 80.0% in ≥3L. Cardiovascular conditions did not impact patients’ clinical outcomes. The most common AEs were infections (30.7%), bleeding (12.9%), fatigue (10.0%), and neutropenia (9.7%), while grade 3–4 atrial fibrillation occurred in 3.9% of patients. No new safety signals were detected. These results strongly support ibrutinib as a valuable treatment option for CLL.

1 April 1998 in Leukemia
Verified
Journal Article
Open access
PDF file
DRD Russo
D Russo
MRM Regazzi
M Regazzi
SSStefano Sacchi
Stefano Sacchi
GVG Visani
G Visani
MLM Lazzarino
M Lazzarino
AMAt Maiolo
At Maiolo
Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNα, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chronic phase. Eighteen patients were treated with ATRA at a dose of 80 mg/m2/day (p.o.), divided into two equal doses after meals, for 7 consecutive days every other week for a maximum of 12 courses (1 course = 1 week on and 1 week off). Pharmacokinetic profiles of ATRA were evaluated during intermittent therapy on days 1 and 7 of course 1; on day 1 of course 2; on day 1 of course 6. Out of the 18 patients treated with ATRA, 11 (61%) went off study before the sixth course of treatment because of progressive hyperleukocytosis (seven cases), or thrombocytosis (one case), or refusal (three cases). Seven (39%) patients completed the first six courses (12 weeks) of treatment with ATRA and two of them (11%) maintained a white blood cell (WBC) <10 × 109/l which was induced by the pretreatment with hydroxyurea. One patient completed the 12th course of ATRA maintaining WBC <10 × 109/l, platelets <500 × 109/l and spleen not palpable. The treatment with ATRA was well tolerated and only one patient discontinued the therapy because of non-hematological side-effects. The area under the concentration-time curve (AUC) decreased significantly (P < 0.001) during the first week of therapy. by adopting an intermittent dosing regimen, 1 week on/ 1 week off (1 course), at the start of courses 2 and 6, we obtained the atra aucs equivalent to the ones achieved on day 1 of course 1. in conclusion, our results showed that atra alone appeared to be unable to control the wbc expansion in the cml patients in chronic phase. moreover, it did not induce any remarkable cytoreductive effects on the platelet count and on the hemoglobin level. the major interest of atra would be in combination with other therapies. if atra was given in combination with ifnα or other agents, dose reduction of these would not be planned. on the basis of the pharmacokinetic profile, atra should be administered intermittently rather than continuously.